Ligand Pharmaceuticals Initiated at Outperform by Oppenheimer
Ligand Pharmaceuticals Analyst Ratings
Oppenheimer Initiates Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $135
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
Ligand Pharmaceuticals Price Target Raised to $110.00/Share From $95.00 by Benchmark
Ligand Pharmaceuticals Analyst Ratings
Ligand Pharmaceuticals Price Target Maintained With a $130.00/Share by RBC Capital
Ligand Pharmaceuticals Analyst Ratings
RBC Capital Reiterates Outperform on Ligand Pharmaceuticals, Maintains $130 Price Target
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $110
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
Ligand Pharmaceuticals Analyst Ratings
RBC Capital Initiates Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $130
Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $110
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
Ligand Pharmaceuticals Analyst Ratings
What 4 Analyst Ratings Have To Say About Ligand Pharmaceuticals
Benchmark Reiterates Buy on Ligand Pharmaceuticals, Maintains $95 Price Target
Ligand Pharmaceuticals Analyst Ratings